Document Detail


Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis.
MedLine Citation:
PMID:  10214749     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the use of estriol in the treatment of experimental autoimmune encephalomyelitis (EAE) and other cell mediated autoimmune diseases. BACKGROUND: Experimental autoimmune encephalomyelitis is a T helper 1 (Th1)-mediated autoimmune demyelinating disease that is a useful model for the study of immune responses in MS. Interestingly, both EAE and MS have been shown to be ameliorated during late pregnancy. METHODS: Estriol, progesterone, and placebo pellets were implanted in mice during the effector phase of adoptive EAE. Disease scores were compared between treatment groups, and autoantigen-specific humoral and cellular responses were examined. RESULTS: Estriol treatment reduced the severity of EAE significantly compared with placebo treatment whereas progesterone treatment had no effect. Estriol doses that induced serum estriol levels that approximated estriol levels during late pregnancy were capable of ameliorating disease. Estriol-treated EAE mice had significantly higher levels of serum antibodies of the immunoglobulin (Ig) G1 isotype specific for the autoantigen myelin basic protein (MBP). Further, MBP-specific T-lymphocyte responses from estriol-treated EAE mice were characterized by significantly increased production of the Th2 cytokine interleukin 10 (IL-10). T lymphocytes were shown to be the primary source of IL-10 within antigen-stimulated splenocyte populations. CONCLUSIONS: Estriol as a hormone involved in immune changes during pregnancy may provide a basis for the novel therapeutic use of estriol for MS and other putative Th1-mediated autoimmune diseases that improve during late pregnancy.
Authors:
S Kim; S M Liva; M A Dalal; M A Verity; R R Voskuhl
Related Documents :
7230139 - Immunological responsiveness of maternal and foetal lymphocytes during normal pregnancy...
20367629 - The immune system in pregnancy: a unique complexity.
18507749 - One single dose of 200 microg of antenatal rhig halves the risk of anti-d immunization ...
3217929 - Hla and red blood group antigens in pregnancy disorders.
9884359 - Ontogeny of the fetal immune system: study on pregnancies with rh-isoimmunization and n...
7045229 - The alloantibody response in the allogeneically pregnant rat. iii. the location of the ...
22510619 - Diagnosis of ectopic pregnancy.
4010599 - Hypertension in pregnancy. a study of 142 women presenting before 32 weeks' gestation.
7844729 - In utero defecation of the nondistressed fetus: a roentgen study in the goat.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Neurology     Volume:  52     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1999 Apr 
Date Detail:
Created Date:  1999-05-12     Completed Date:  1999-05-12     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1230-8     Citation Subset:  AIM; IM; X    
Affiliation:
Department of Neurology, University of California Los Angeles School of Medicine, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Autoimmune Diseases / immunology*
Brain / immunology
Disease Models, Animal
Encephalomyelitis, Autoimmune, Experimental / drug therapy*,  immunology*
Estriol / blood,  immunology*,  therapeutic use*
Female
Interleukin-10 / biosynthesis
Male
Mice
Multiple Sclerosis / immunology*
Myelin Basic Proteins / immunology
Pregnancy
Th1 Cells / immunology
Grant Support
ID/Acronym/Agency:
NS36680-01/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Myelin Basic Proteins; 130068-27-8/Interleukin-10; 50-27-1/Estriol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?
Next Document:  Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.